Takeda Pharmaceutical Company Limited announced the exercise of its option to acquire GammaDelta Therapeutics Limited (“GammaDelta”), a company focused on exploiting the unique properties of gamma delta (γδ) T cells for immunotherapy. Through the acquisition, Takeda will obtain GammaDelta’s allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy platforms, which includes both blood-derived and tissue-derived platforms, in addition to early-stage cell therapy programs.
- Read more about Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/takeda-to-acquire-gammadelta-therapeutics-to-accelerate-development-of-allogeneic-%CE%B3%CE%B4t-cell-therapies-addressing-solid-tumors
No comments:
Post a Comment